ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

Autor: Marit A. C. Vermunt, Debbie G. J. Robbrecht, Lot A. Devriese, Julie M. Janssen, Bas Thijssen, Marianne Keessen, Maarten vanEijk, Rob Kessels, Ferry A. L. M. Eskens, Jos H. Beijnen, Niven Mehra, Andries M. Bergman

Publikováno v: Cancer Reports, Vol 4, Iss 4, Pp n/a-n/a (2021)

Abstract Background ModraDoc006 is an oral formulation of docetaxel, which is co‐administered with the cytochrome P450 3A4 and P‐glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase

Externí odkaz: https://doaj.org/article/ad84cb565b37425dadb093bae9e81fac

The intravenous to oral switch of taxanes: strategies and current clinical developments

Autor: Marit A C Vermunt, Jos H. Beijnen, Eric van der Putten, Andries M. Bergman

Publikováno v: Future Oncology. 17:1379-1399

The taxanes paclitaxel, docetaxel and cabazitaxel are important anticancer agents that are widely used as intravenous treatment for several solid tumor types. Switching from intravenous to oral treatment can be more convenient for patients, improve c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e02be6e588274887afc058f55d3647d
https://doi.org/10.2217/fon-2020-0876

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

Autor: Alain Ravaud, Ganesh Mugundu, Liselot Valkenburg-van Iersel, Lone Ottesen, Karen So, Marit A C Vermunt, Fiona C Thistlethwaite, Yan Li, Mariette Labots, Mario Campone, Mats Någård, Patricia Roxburgh, Mei-Lin Ah-See

Publikováno v: Cancer Chemotherapy and Pharmacology, 86(1), 97-108. Springer Verlag
Någård, M, Ah-See, M-L, So, K, Vermunt, M, Thistlethwaite, F, Labots, M, Roxburgh, P, Ravaud, A, Campone, M, Valkenburg-van Iersel, L, Ottesen, L, Li, Y & Mugundu, G 2020, ' Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors ', Cancer Chemotherapy and Pharmacology, vol. 86, no. 1, pp. 97-108 . https://doi.org/10.1007/s00280-020-04101-4
Cancer Chemotherapy and Pharmacology

Purpose To support future dosing recommendations, the effect of food on the pharmacokinetics of adavosertib, a first-in-class, small-molecule reversible inhibitor of WEE1 kinase, was assessed in patients with advanced solid tumors. Methods In this Ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41b79a45c1b4aa90b1e59f2e5e2bf9ed
https://cris.maastrichtuniversity.nl/en/publications/ceaf7d64-ddd9-4f1c-ab7b-f9010a0a093c

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients

Autor: Marianne Keessen, Debbie Robbrecht, Rob Kessels, Marit A C Vermunt, Bas Thijssen, Niven Mehra, Ferry A.L.M. Eskens, Andries M. Bergman, Lot A. Devriese, Julie M Janssen, Maarten van Eijk, Jos H. Beijnen

Publikováno v: Cancer Reports, Vol 4, Iss 4, Pp n/a-n/a (2021)
Cancer Reports, 4(4):e1367. Wiley-Blackwell Publishing Ltd
Cancer Reports

BACKGROUND: ModraDoc006 is an oral formulation of docetaxel, which is co-administered with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase I trials in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::143bb499c3c73d62ce9cbad339d122d7
https://doi.org/10.1002/cnr2.1367

A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors

Autor: Johannes J. Moes, Frederik E. Stuurman, Alwin D. R. Huitema, Marit A C Vermunt, Emilia Sawicki, Vincent A. de Weger, Jeroen J M A Hendrikx, Serena Marchetti, Jos H. Beijnen, David Damoiseaux, Bastiaan Nuijen, Marja Mergui-Roelvink, Hilde Rosing, Artur M. Burylo

Publikováno v: Clinical pharmacology in drug developmentReferences. 10(6)

ModraPac001 (MP1) and ModraPac005 (MP5) are novel oral paclitaxel formulations that are coadministered with the cytochrome P450 3A4 inhibitor ritonavir (r), enabling daily low-dose metronomic (LDM) treatment. The primary aim of this study was to dete

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d7f26a4a7b95a187fccb4da631ba949
https://pubmed.ncbi.nlm.nih.gov/33021083